Funding will advance commercialization of the Stentrode™ BCI platform and expand AI and engineering operations in New York and San Diego

Synchron, a leader in non-surgical brain-computer interface (BCI) technology, announced today it has raised a $200 million Series D financing round. The funding will accelerate commercialization of the company’s first-generation Stentrode™ BCI platform, while advancing development of a frontier next-generation interface.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106150841/en/

Photo caption: The Stentrode™ Endovascular Electrode Array Photo credit: Synchron

The round was led by Double Point Ventures, alongside existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI and METIS. New investors include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT. The financing brings Synchron’s total funding to $345 million.

Synchron’s Stentrode™ BCI platform is the world’s first endovascular brain-computer interface, designed to translate brain activity into digital commands without open-brain surgery. Placed via a non-surgical catheter procedure, the Stentrode interfaces with the motor cortex through the blood vessels, recording and transmitting neural signals wirelessly to enable hands-free control of digital devices. Stentrode BCIs have been placed in 10 patients with paralysis to date, across clinical trials in the U.S. and Australia.

Synchron was the first BCI company to integrate Apple’s BCI-human interface device (BCI-HID), having co-developed a Bluetooth-based iOS protocol that connects brain activity directly to Apple devices using Switch Control, including iPad, iPhone and Vision Pro - no touch, voice, or eye-tracking required.

“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis,” said Tom Oxley, CEO and Founder, Synchron. “This funding brings us closer to commercializing the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”

An expanding Cognitive AI division in New York City will be training models that learn from brain data to decode thought in real time. In parallel, its new San Diego engineering hub has been established to build the world’s most advanced brain interface.

“Synchron is building the first truly scalable, minimally invasive brain-computer interface that can be deployed in everyday healthcare,” said Campbell Murray, MD, Co-Founder and Managing Partner at Double Point Ventures. “Its fusion of neurovascular access, breakthrough device engineering, and adaptive AI marks a fundamental step toward restoring digital agency to people with paralysis.”

“Synchron’s work is expanding the frontier of what’s possible between the human brain and technology,” said Dr. Bob Langer, Executive Chairman, T.Rx Capital. “This next phase brings us closer to a future where brain interfaces can potentially unlock entirely new dimensions for healthcare.”

With this Series D financing, Synchron will accelerate pivotal trials, prepare for commercial launch of the Stentrode™ BCI system, and continue hiring engineers, neuroscientists, and operators to advance the next generation of brain-computer interfaces.

About Synchron

Synchron is pioneering minimally invasive brain-computer interfaces (BCIs) to restore communication, mobility, and independence for people with paralysis. Its Stentrode™ platform is the first endovascular BCI designed to translate thought into digital action without open-brain surgery, combining neurointerventional access, device engineering, and NeuroAI to create scalable, real-world neural interfaces. The company is headquartered in New York, NY, with an engineering and research hub in San Diego, CA. For more information, visit www.synchron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251106150841/en/